Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
April 4, 2014
- Sales Rep Wrote Out Side Effect Grades for Doctors in SIGN Trial: Panel
April 3, 2014
- Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
- COO Weber Wants Takeda to Be Global Leader
April 3, 2014
- Mochida Aims for Sales of 110 Billion Yen with Generic Sales of Over 10 Billion Yen in FY2016
April 3, 2014
- Astellas Establishes “Regenerative Medicine Unit”; Aims to Establish Basic Technologies within 1 to 2 Years
April 3, 2014
- 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
- Latuda Granted European Regulatory Approval: DSP, Takeda
April 2, 2014
- Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
April 2, 2014
- Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
April 2, 2014
- Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
April 2, 2014
- US Biotech NPS Takes Aim at Japan Debut around 2017
April 1, 2014
- Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
- Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
April 1, 2014
- Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
- AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
March 31, 2014
- Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
- Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
March 28, 2014
- Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
March 28, 2014
- Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
March 27, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…